Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;15:1593–1604. doi: 10.2147/JAA.S383012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Senna et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Annualized exacerbation rates (AER) of any severity (A) and for severe exacerbations (B) during benralizumab treatment in severe eosinophilic asthma (SEA) patients with BEC 300–450 cells/mm³ and in the total population (N=157 at baseline, N=135 at 48 weeks in the total population; N=32 at baseline, N=28 at 48 weeks in the BEC 300–450 subset); (C) Asthma control test (ACT) improvement at different timepoints in total population and BEC 300–450 subset; (D) Pre-BD FEV₁ (pre-bronchodilator forced expiratory volume in the first second) change over time in total population and BEC 300–450 subgroup.